KLRC1 and ovarian cancer: While binding of NKG2A to HLA-E is known to inhibit NK cell responses, ovarian cancer cell lines that were treated with the anti-NKG2A mAb monalizumab showed profound antitumor responses and significantly improved cetuximab-mediated ADCC (173, 174).